Citigroup’s BeOne Medicines Ltd ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.16M Sell
14,000
-6,000
-30% -$1.94M ﹤0.01% 2110
2025
Q4
$6.08M Hold
20,000
﹤0.01% 1880
2025
Q3
$6.81M Buy
+20,000
New +$6.07M ﹤0.01% 1769
2025
Q1
Sell
-29,900
Closed -$5.52M 6063
2024
Q4
$5.52M Buy
+29,900
New +$6.11M ﹤0.01% 1857
2024
Q3
Sell
-15,000
Closed -$2.14M 5829
2024
Q2
$2.14M Buy
+15,000
New +$2.31M ﹤0.01% 2295

Other funds holding ONC

Citigroup's ONC Position: Q1 2026 in Review

Citigroup increased its BeOne Medicines Ltd (ONC) stake by 82% in Q1 2026, buying an estimated $1.49M and bringing the position to 10,188 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2370.

Citigroup first reported a position in ONC in Q1 2016 and has held it in 39 quarters since. The position peaked at $21.9M in Q3 2018. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

  • Citigroup held 10,188 shares of BeOne Medicines Ltd worth $3.03M as of Q1 2026.
  • Citigroup bought 4,590 BeOne Medicines Ltd shares in Q1 2026, an estimated $1.49M.
  • BeOne Medicines Ltd made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2370 holding.
  • Citigroup first reported a position in BeOne Medicines Ltd in Q1 2016 and has held it in 39 quarters since.
  • Citigroup's BeOne Medicines Ltd position peaked at $21.9M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.